3-碘-1,2-苯二胺 | 34446-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-碘-1,2-苯二胺
• 英文名称: 3-iodo-benzene-1,2-diamine
• 英文别名: 3-Iod-o-phenylendiamin；3-Iodobenzene-1,2-diamine
• CAS: 34446-43-0
• 化学式: C₆H₇IN₂
• 分子量: 234.039
• InChiKey: ZPGYMGXNLJHVHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  5-methyl-benzo[b]thiophene-2,3-dione 、 3-碘-1,2-苯二胺 以 溶剂黄146 为溶剂， 生成 10-iodo-2-methyl-benzo[4,5]thieno[2,3-b]quinoxaline
  参考文献：
  名称：

  Banerji,K.D. et al., Journal of the Indian Chemical Society, 1973, vol. 50, p. 268 - 270

  摘要：

  DOI：

文献信息

• Aza- indolyl derivatives for treating obesity
  申请人：——

  公开号：US20010025039A1

  公开（公告）日：2001-09-27

  Novel compounds of formula (I): 1 wherein X 1 , X 2 , X 3 and X 4 , n, R 1 , R 2 and R 3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.

  式(I)的新化合物：其中X1、X2、X3和X4、n、R1、R2和R3在规范中有定义，化合物的药物可接受的盐和前药具有治疗用途。这些化合物对于治疗中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症和睡眠呼吸暂停症等疾病有用。它们特别适用于肥胖症的治疗。
• New aza-indolyl derivatives for the treatment of obesity
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1132389A1

  公开（公告）日：2001-09-12

  The present invention refers to chemical compounds of formula (I); wherein X1, X2, X3 and X4, n, R1, R2 and R3 and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  本发明涉及式（I）化合物； 其中X1、X2、X3和X4、n、R1、R2和R3及其药学上可接受的盐和原药，以及它们在治疗中的用途，特别是用于治疗中枢神经系统疾病；中枢神经系统损伤；心血管疾病；胃肠道疾病；糖尿病和睡眠呼吸暂停，尤其是用于治疗肥胖症。
• Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
  申请人：Lu Qing-Bin

  公开号：US10463662B2

  公开（公告）日：2019-11-05

  Disclosed herein are non-platinum-based (NPB) anti-cancer compounds useful for targeted chemotherapy, e.g., to generate anti-cancer effects for the treatment of cancer and other disorders while having no or minimal toxicity. The compounds N have the general formula I: (I) wherein A represents an aromatic core; at least one of Ra and Rb is an electron transfer promoter as defined herein, e.g., NH2; and at least one of Rc is a leaving group as defined herein, e.g., halogen; and the remainder of the molecule is as defined herein. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the anti-cancer compounds are also disclosed.

  本文公开的是非铂基（NPB）抗癌化合物，可用于靶向化疗，例如，产生抗癌效果以治疗癌症和其他疾病，同时无毒性或毒性最小。化合物 N 具有通式 I：(I) 其中 A 代表芳香族核心；Ra 和 Rb 中至少一个是本文定义的电子转移促进剂，如 NH2；Rc 中至少一个是本文定义的离去基团，如卤素；分子的其余部分如本文定义。还公开了包含抗癌化合物的药物组合物、方法、用途、试剂盒和商业包装。
• Carbon-13 NMR studies on some 5-substituted quinoxalines
  作者：Ulrich Hollstein、Galen E. Krisov

  DOI：10.1002/mrc.1270140417

  日期：1980.10

  AbstractEleven 5‐substituted quinoxalines (NO2, NH2, COOH, OCH3, CH3, OH, F, Cl, Br, I, CN, the latter five not reported previously) have been synthesized by standard methods. Their 13C NMR spectra have been measured in DMSO‐d6 and assigned on the basis of substituent parameters, by line widths and by intensities. The chemical shifts compare favorably with those calculated using benzene substituent parameters, and are very close to those of corresponding carbons in 1‐substituted phenazines. The correlation with the chemical shifts of the corresponding positions in 1‐substituted naphthalenes is also close except for those of carbons 4a and 8a in the quinoxalines which, due to their proximity to nitrogen, are downfield (in some cases 12 ppm) of the signals of the corresponding carbons in naphthalene. 5‐Fluoroquinoxaline was also measured in CDCl3, CD3COCD3, CD3CN, CD3OD, C6D6 and CD3COOD. In all solvents an abnormally low 2J(CF) (∼ 12 Hz) was found for C‐4a and no CF spin‐spin splitting could be detected for the three‐bond coupling of C‐8a. Similar abnormalities were found in 2‐fluoroaniline and 2‐fluoroacetanilide. There are linear relationships between the Q parameter of the substituent and the chemical shift of carbons 4a, 5 and 6. A linear relationship also exists between the chemical shift of C‐8 (‘para’ position) and the Hammett σp parameter of the substituent.
• NEW AZA-INDOLYL DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1274711A1

  公开（公告）日：2003-01-15